MESO Stock Risk & Deep Value Analysis
Mesoblast Ltd
DVR Score
out of 10
What You Need to Know About MESO Stock
We analyzed Mesoblast Ltd using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran MESO through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
MESO Risk Analysis & Red Flags
What Could Go Wrong
Despite an excellent cash runway, future clinical trial failures for key pipeline assets like DMD or CLBP could significantly diminish the company's long-term revenue potential and lead to a substantial drop in valuation, as the market is currently pricing in multiple successes.
Risk Matrix
Overall
Aggressive
Financial
Medium
Market
Medium
Competitive
Medium
Execution
Medium
Regulatory
High
Red Flags
- ⚠
Company remains unprofitable; while cash burn is significantly reduced, the path to sustained free cash flow positivity is contingent on pipeline success.
- ⚠
Heavy reliance on successful and timely regulatory approvals for future substantial revenue generation (DMD, CLBP).
- ⚠
Lack of detailed segment-specific profitability metrics (e.g., gross margins by product) in publicly available summaries.
Upcoming Risk Events
- 📅
Regulatory setbacks or delays for DMD or CLBP trials
- 📅
Slower-than-expected Ryoncil sales growth or market penetration issues
- 📅
New competitor emerging with a superior or cheaper cell therapy platform
When to Reconsider
- 🚪
Any significant negative clinical trial results or regulatory rejection for DMD or CLBP.
- 🚪
Ryoncil revenue growth decelerates to less than 10% quarter-over-quarter for two consecutive quarters.
- 🚪
A major unexpected capital raise causing significant shareholder dilution without a corresponding major clinical or commercial success.
Unlock MESO Risk Analysis & Red Flags
Create a free account to see the full analysis
Investment Thesis
Mesoblast is a compelling high-risk, high-reward investment driven by its validated allogeneic mesenchymal stromal cell platform, which has successfully brought Ryoncil to market with strong commercial uptake. With a significantly extended cash runway due to controlled burn and promising late-stage pipeline assets targeting large markets like Duchenne muscular dystrophy and chronic low back pain, the company is strategically positioned for exponential growth and potential market leadership in cell-based inflammatory disease treatments.
Is MESO Stock Undervalued?
Unlock the full AI analysis for MESO
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
MESO Price Targets & Strategy
12-Month Target
$35.00
Bull Case
$50.00
Bear Case
$10.00
Valuation Basis
Target reflects ~20x P/S on projected FY2027 run-rate revenue of $250M from Ryoncil and discounted future value of advanced pipeline assets (DMD, CLBP).
Entry Strategy
Dollar-cost average between $15-$18, utilizing any dips to accumulate shares near current support levels.
Exit Strategy
Take partial profit at $50-$60 to de-risk, re-evaluate at $100. Implement a stop-loss order if the stock breaks below $12.
Portfolio Allocation
10% for aggressive risk tolerance
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is MESO Financially Healthy?
Profitability
Gross Margin
57.98%
Operating Margin
-115.66%
Net Margin
-144.33%
Return on Equity
-16.10%
Revenue Growth
1053.16%
EPS
$-0.07
Balance Sheet
Current Ratio
1.99
Quick Ratio
1.72
Debt/Equity
0.21
Cash & Equivalents
$121.80M
Other
Beta (Volatility)
2.35
Does MESO Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
3 Identified
The moat is likely durable for 10-20 years. Significant R&D investment, clinical trial successes, and regulatory navigation create substantial barriers to entry, which will be further strengthened by future approvals in DMD and CLBP.
Moat Erosion Risks
- •Emergence of superior or cheaper alternative therapies (e.g., next-generation gene therapies for DMD).
- •Challenges to Mesoblast's intellectual property or patent expirations.
- •Competitors developing alternative allogeneic cell sources or more efficient manufacturing processes.
MESO Competitive Moat Analysis
Sign up to see competitive advantages
MESO Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Bullish, driven by recent positive earnings, pipeline advancements, and reduced cash burn.
Institutional Sentiment
Positive, indicated by the company's strong financial health rating and successful pipeline execution; likely to attract increased institutional interest.
Insider Activity (Form 4)
Two insider buys in the past three months with zero insider sales, signaling strong management confidence in future prospects.
Options Flow
Normal options activity
Earnings Intelligence
Next Earnings
Estimated mid-July 2026
Surprise Probability
Medium
Historical Earnings Pattern
Recent positive Q1 2026 results led to a positive market sentiment, suggesting potential for upside on continued execution and de-risking of financial position.
Key Metrics to Watch
Competitive Position
Top Competitor
Sarepta Therapeutics (SRPT) for DMD indication, but MESO's allogeneic MSC platform is unique.
Market Share Trend
Gaining, especially with Ryoncil as the first FDA-approved allogeneic MSC therapy for SR-aGVHD and potential expansion into new indications.
Valuation vs Peers
Trading at a high Price/Sales multiple (~17x annualized Q1 net sales), justified by the unique platform, approved product, and multiple late-stage, large-market pipeline assets.
Competitive Advantages
- •First FDA-approved allogeneic MSC therapy for SR-aGVHD (Ryoncil).
- •Proprietary, scalable allogeneic mesenchymal stromal cell (MSC) platform technology.
- •Broad late-stage pipeline targeting multiple large unmet medical needs (DMD, CLBP).
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive MESO Stock Higher?
Near-Term (0-6 months)
- •Q2 2026 Earnings report (Estimated mid-July 2026)
- •Continued Ryoncil commercial ramp-up and sales growth
- •Updates on DMD registrational trial enrollment and progress
Medium-Term (6-18 months)
- •Phase 3 data readout for rexlemestrocel-L (chronic low back pain)
- •Potential BLA submission for rexlemestrocel-L (CLBP) if data is positive
- •Interim data or significant updates on the DMD registrational trial
Long-Term (18+ months)
- •Potential FDA approval and commercial launch of rexlemestrocel-L (CLBP)
- •Potential FDA approval and commercial launch of DMD therapy
- •Global expansion and broader platform adoption for other inflammatory diseases
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for MESO?
- ✓
Consistent double-digit sequential growth in Ryoncil net revenues.
- ✓
Positive clinical trial data readouts and regulatory progress for rexlemestrocel-L (CLBP) and DMD.
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Mesoblast Ltd Makes Money
Mesoblast Ltd. is a biotechnology company focused on developing and commercializing innovative 'off-the-shelf' cellular medicines derived from mesenchymal stromal cells (MSCs) to treat various inflammatory diseases. The company primarily generates revenue from the sales of its FDA-approved product, Ryoncil (remestemcel-L), used to treat steroid-refractory acute Graft Versus Host Disease (SR-aGVHD) in pediatric patients, which it sells to hospitals and specialized treatment centers. Its core strategy involves leveraging its proprietary cell therapy platform to advance a pipeline of late-stage assets through clinical trials and regulatory approvals, aiming to commercialize these products or partner with larger pharmaceutical companies to address significant unmet medical needs.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Mesoblast Ltd (MESO)?
As of April 30, 2026, Mesoblast Ltd has a DVR Score of 8.3 out of 10, placing it in the "Hidden Gem" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Mesoblast Ltd?
Mesoblast Ltd's market capitalization is approximately $2.9B..
What is the risk level for MESO stock?
Our analysis rates Mesoblast Ltd's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
Is Mesoblast Ltd's revenue growing?
Mesoblast Ltd has reported revenue growth of 1053.2%. The company is showing strong top-line momentum.
Is MESO stock profitable?
Mesoblast Ltd has a profit margin of -144.3%. The company is currently unprofitable.
How often is the MESO DVR analysis updated?
Our AI-powered analysis of Mesoblast Ltd is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 30, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for MESO (Mesoblast Ltd) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.